HLX23 / Fosun Pharma - LARVOL DELTA

A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Shanghai Henlius Biotech | N=30 ➔ 0 | Trial completion date: Mar 2024 ➔ Jan 2023 | Recruiting ➔ Withdrawn | Trial primary completion date: May 2023 ➔ Jan 2023

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial withdrawal • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • CD68

A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Shanghai Henlius Biotech | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2023 ➔ Mar 2024 | Trial primary completion date: Jul 2022 ➔ May 2023

Enrollment open • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • CD68

Fosun Pharma’s anti-CD73 mAb nodded for solid tumors trials in US (GBI Health) - "China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (600196.SH, 02196.HK) announced that its HLX23, a monoclonal antibody (mAb) targeting CD73, has obtained clinical trial approval from the US FDA. The drug candidate will be assessed as a treatment for advanced solid tumors."

IND • Oncology • Solid Tumor

A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor (clinicaltrials.gov) - P1; N=30; Not yet recruiting; Sponsor: Shanghai Henlius Biotech

Clinical • New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor